Food and Drug Authority penalties: 23 facilities found to be in violation of drug regulations

The Food and Drug Authority's efforts in achieving drug security

In a decisive step to ensure public health security, Food and Drug Authority (SFDA) announced the release of its report on facilities' compliance with the requirement to provide medicines and report their movements through the electronic pharmaceutical tracking system, "Rasad." The latest report, covering the period from February to March, revealed that 23 facilities were found to be in violation of the stipulated standards and requirements, resulting in the imposition of strict financial and administrative penalties.

The Saudi Food and Drug Authority (SFDA) was established with the primary objective of protecting public health by ensuring the safety of food, drugs, and medical devices. In line with the Kingdom's technological advancements and digital transformation, the electronic tracking system "Rasad" was launched. This advanced system tracks and traces all human medicines from the moment they leave the manufacturing facility, whether local or international, until they reach the end consumer. This system was a historic response to the critical need to combat commercial fraud in the pharmaceutical sector and ensure the uninterrupted supply of vital medical products upon which millions of patients depend.

Details of observed violations and financial penalties

Official reports revealed that the violations detected spanned several vital aspects of the supply chain. Two facilities failed to maintain a six-month supply of all their registered products and were unable to compensate for any shortages within a maximum of three months. Seven other facilities failed to provide their registered products despite low market demand or consumption. Furthermore, the report identified nine facilities that failed to report anticipated shortages or disruptions in drug supplies at least six months in advance. Finally, five facilities failed to report drug movement directly. As a result of these violations, the total fines imposed amounted to SAR 1,232,700.

The expected impact of strict measures on the health sector

These stringent regulatory measures are of paramount importance and have a far-reaching impact. Domestically, they ensure the stability of the Saudi pharmaceutical market, providing citizens and residents with complete peace of mind regarding the uninterrupted availability of their medications. Regionally, the Kingdom sets a gold standard in pharmaceutical regulation, reinforcing its position as a regional leader in managing medical supply chains. Internationally, this transparency and rigorous enforcement of regulations contribute to attracting further foreign investment from major global pharmaceutical companies, which are always seeking markets with a robust and reliable regulatory environment that protects intellectual property rights and combats counterfeit drugs.

Deterrent penalties to ensure compliance by pharmaceutical establishments

To ensure such violations are not repeated, the relevant authorities have warned that any laxity in enforcing the regulations will be met with firm action. According to the Law of Pharmaceutical and Herbal Establishments and its implementing regulations, penalties are not limited to simple fines but can escalate to up to five million Saudi riyals. In addition to financial penalties, the law allows for severe administrative sanctions, including the temporary closure of the offending pharmaceutical establishment for a period not exceeding 180 days, or even the permanent revocation of its license, underscoring that human health is a red line that cannot be compromised.